The identification of the different molecular causes of congenital nephrogenic diabetes insipidus (NDI), a disorder characterized by renal insensitivity to the antidiuretic effect of arginine vasopressin, has been of indispensable importance for understanding the cellular processes involved in diuresis and antidiuresis. In most cases, NDI is X-linked and caused by mutations in the vasopressin type-2 receptor (V2R) gene. Mutations in the aquaporin-2 (AQP2) water channel gene are responsible for the autosomal recessive and rare dominant forms of NDI. By in vitro expression, it has been shown that the majority of V2R mutants and all AQP2 mutants found in recessive NDI are misfolded and retained within the endoplasmic reticulum (ER). Functional analysis of one of the mutations identified in dominant NDI showed that this mutant is properly folded and transported out of the ER, but is retained in the Golgi region. In addition, this mutant, in contrast to mutants found in recessive NDI, is able to heterotetramerize with wild-type AQP2. The resulting complex is hindered in its transport to the membrane, a finding that explains the dominantnegative effect of this mutation. Several new methodologies focused on the molecular defects causing NDI are presently being investigated in vitro and might eventually develop into useful therapeutic strategies.
Introduction
In recent years our understanding of the vasopressinmediated renal concentrating mechanisms has increased enormously through the identification of the molecular defects underlying congenital nephrogenic diabetes insipidus (NDI), a hereditary disorder characterized by renal insensitivity to the antidiuretic action of arginine vasopressin (AVP), resulting in a severe concentration defect. NDI was first described more then one century ago by McIlraith [1] and for a long time was of interest to clinicians only. However, since the identification of the genes underlying the different genetic types of this disorder, a renewed interest in NDI, now shared by (molecular) biologists, physiologists, and biochemists also, can be noted.
In addition to providing new and surprising insight into the cellular mechanisms involved in diuresis and antidiuresis, the elucidation of the genetic and cellular defects in NDI has significantly improved the diagnosis and differential diagnosis of the disorder, and has enabled accurate genetic counseling of patients and their family members. Furthermore, new therapies for NDI, based on the understanding of the cellular defects in this disorder, are now being developed and seem promising, although their efficacy and safety still need to be examined. After a short review of the current knowledge of the normal physiology of the renal collecting duct water permeability, we will discuss the molecular and cellular defects underlying the different types of NDI. Finally we will briefly discuss some potential new therapies.
Physiology of the action of vasopressin in the collecting ducts
The physiological action of vasopressin on the renal collecting duct cells has been one of the most intensively studied processes in the kidney. In response to high serum osmolality or a reduction in effective circulating blood volume, AVP is secreted by the posterior pituitary. In the collecting duct of the kidney, AVP binds to the vasopressin type 2 receptor (V2R) on the basolateral membrane of principal cells (Fig. 1) . The interaction between AVP and its V2R initiates the activation of adenylate cyclase via the intermediacy of Gs, resulting in an increase of intracellular cAMP concentration. The elevated cAMP levels stimulate protein kinase A (PKA), which in turn initiates a redistribution of aquaporin-2 (AQP2) water channels from intracellular vesicles to the apical plasma membrane, rendering this membrane water permeable. Phosphorylation by PKA of serine at position 256 in the cytoplasmic COOH-terminus of AQP2 is essential for its redistribution [2, 3] . Interesting in this respect is that in an unstimulated steady state condition, phosphorylated AQP2 could be detected in intracellular vesicles [4] . However, AQP2 is expressed as a homotetramer [5] and recent studies using oocytes as a model system indicated that for a plasma membrane localization three out of four monomers in an AQP2 tetramer need to be phosphorylated [6] . The increase in apical membrane permeability allows water to flow from the tubule lumen, via AQP2 in the apical membrane and via AQP3 and AQP4 water channels in the basolateral membrane, to the hypertonic medullary interstitium. This then leads to the formation of concentrated urine. Withdrawal of vasopressin triggers the endocytosis of AQP2-containing vesicles and restores the water-impermeable state of the apical side of the cell. The molecular machinery for the docking and fusion of AQP2-containing vesicles with the apical membrane has some similarity to the process of synaptic vesicle fusion with the presynaptic membrane and involves vesicle (v) SNAREs (soluble NSF attachment protein receptors) and target membrane (t) SNAREs. Thus, in subcellular fractions from rat kidney, enriched for AQP2-containing vesicles, the v-SNARE synaptobrevin was found, as well as the fusion mediating protein SNAP23 [7] [8] [9] [10] . The potential t-SNARE syntaxin-4 was identified at the apical plasma membrane of rat kidney collecting duct principal cells [11] . Rab3A, a member of the Rab family of GTPases, involved in exo-and endocytotic membrane trafficking, is also believed to play a role in AQP2 translocation to the apical membrane [9, 12] . In addition, it has been shown that both the microtubule-associated motor protein dynein and the associated dynactin-complex, which catalyze transport of vesicles along microtubules, are important in vasopressin-regulated trafficking of these vesicles [13] . Recently, evidence for a critical role of calcium as an intracellular mediator of the vasopressin-induced trafficking of AQP2 has been found [14] . The translocation of AQP2 from the intracellular vesicle to the plasma membrane can also be stimulated by cAMP-independent pathways. Thus, Bouley et al. have shown that nitric oxide and atrial natriuretic factor stimulate the insertion of AQP2 in renal epithelial cells via a cGMP dependent pathway [15] . The importance of this pathway is as yet unclear.
NDI is a heterogeneous disorder
Three different inheritance patterns of NDI have been recognized. In most cases (about 90%), NDI is transmitted as an X-linked recessive trait (MIM 304800) caused by mutations in the V 2 receptor gene. A minority of patients (about 10%) show an autosomal recessive (MIM 222000) or dominant trait (MIM 125800) as a result of mutations in the AVP-sensitive aquaporin-2 water channel gene. Although there are a few exceptions (see later), all NDI patients share the same clinical pattern [16] ; due to the insensitivity of the renal distal nephron to the antidiuretic effect of AVP, large volumes of hypotonic urine are excreted, which may lead to severe dehydration. Patients present in their first year of life with non-specific symptoms such as anorexia, vomiting, fever, growth retardation and developmental delay. After infancy, the clinical picture is dominated by the less alarming symptoms of polyuria and polydipsia. The most severe complication of the disorder is mental retardation, which is assumed to be a sequel of severe brain dehydration. Nowadays this complication is rare due to earlier recognition and treatment of NDI. Exact estimates of the current frequency of mental retardation under modern treatment are unknown, but in the largest psychometric study ever reported only 2 of the 17 male NDI patients (aged 3-30 years) tested had a total intelligence quotient more than 2 SD below the norm. Fourteen patients had an intelligence score within or above the normal range and one patient had a general index score between -1 and -2 SD [17].
The X-linked form of NDI
The sex-linked form of NDI is caused by mutations in the human V2 receptor, which was isolated in 1992 by Birnbaumer et al. (AVPR2; Genbank accession number L22206) applying a genomic expression cloning approach [18] . The human V 2 receptor gene is relatively small and consists of three exons separated by two short intervening sequences (introns) [19] . The mRNA has been found exclusively in the kidney, specifically in the cortical and medullary collecting ducts. The human V2 receptor protein consists of 371 amino acids, has a predicted molecular weight of approximately 41 kDa and shares the general structure of a G-protein-coupled receptor, with seven hydrophobic transmembrane helices, connected by extracellular and intracellular loops. The receptor contains one unique consensus sequence site for N-linked glycosylation in the extracellular amino terminus [20] , and phosphorylation sites for G-protein-coupled receptor kinases (GRK) represented by a serine cluster in the carboxy-terminus [21, 22] . The amino-terminal part of the protein including the first transmembrane domain and the positively charged first intracellular loop are important for proper insertion and orientation in the membrane [23] . A conserved glutamate-dileucine motif in the intracellular carboxy-terminal part of the receptor is essential for receptor transport from the endoplasmic reticulum (ER) to the Golgi apparatus [24] . Two conserved adjacent cysteines in the C-terminus are palmitoylated, thereby anchoring the carboxy tail to the plasma membrane and controlling the tertiary structure of this region of the receptor [25] . To date, more than 180 distinct putative disease-causing mutations in the V 2 receptor gene have been identified in families with X-linked NDI (see http://www.medcon.mcgill.ca/ nephros). The mutations are not clustered in one domain of the receptor, but are scattered throughout the protein, except for the part coding for the N-and C-terminal tails of the receptor. The finding of so many mutations in the V 2 receptor gene in patients with NDI demonstrates that the disorder is highly heterogeneous at the molecular level. The mutations consist of nucleotide deletions and insertions, which might be attributed to slipped mispairing during DNA replication, and nucleotide substitutions, some of which could be the result of 5-methylcytosine deamination at a CpG dinucleotide. In addition, some splice-site mutations and large deletions have been identified [26] [27] [28] . The impact of several mutations on the function of the V 2 receptor has been studied in invitro expression systems, such as COS-7 cells, which allowed a further classification of the genotypes based on the cell-biological outcome, similar to what has been done for other proteins [29] [30] [31] [32] . The first class of mutations (class I) results in defects in the synthesis of stable mRNA, which precludes the formation of sufficient amounts of protein. Mutations resulting in aberrant splicing, frame-shifts and premature termination of translation belong to this first category. Most of the truncated receptor proteins found in NDI patients result in a complete lack of receptors present on the cell surface and consequently preclude specific function of the receptor. The majority of mutations found in X-linked NDI belongs to the second class (class II), in which the translation of the protein is completed, but the abnormal protein is misfolded or improperly assembled and trapped in the endoplasmic reticulum (ER). Subsequently, such mutant proteins are often targeted to proteasomes for degradation. Therefore, class II mutations also lead to severely reduced or absent receptor expression on the cell surface. Most missense mutations, and in-frame-deletions and some nonsense mutations in the V2R, fall in this class II and, except for some mutations in the extra-and intracellular loops (R113W, R143P, G201D, R337stop, E242stop), most of these mutations are located in transmembrane domains (L44P, I46K, L59P, L62P, L62-64del, L83P, L83Q, A84D, I130F, R137H, R143P, W164S, S167T, S167L, S167A, I209F, V287del, Y280C, L292P, A294P) [reviews in [33] [34] [35] [36] [37] [38] [39] [40] . A few of the missense-and frameshift mutations, however, have been shown not to significantly alter protein abundance at the cell surface, but either impair the coupling efficiency of the receptor to the stimulating G protein (class III mutations) or reduce AVP-binding affinity (class IV mutations). As yet, only a few mutations have been identified that belong to class III. These mutations are found in the lower half of the transmembrane regions (D85N, P322S/P) and within the second intracellular loop (R137H) [39, 41] . The study by Rosenthal et al.
[41] demonstrating disturbed G-protein activation of the in-vitro-expressed R137H mutation stresses the importance of the highly conserved DRY/H motif in the second intracellular loop for G-protein activation, which is known for other G-protein-coupled receptors also [42] . In conflict with the study by Rosenthal, others have reported that the R137H mutant is almost completely retained in the cell interior [36] . Class IV mutations are mainly found in the first, second and sixth transmembrane domain (L44F, A84D, V88M, Y128S, P286R, V277A) and in the first and second extracellular loops (W99R, F105V, R181C, G185C, ∆R202, R202C, T204N, Y205C, V206D, R113W) [reviews in 33; 34, 37, 40]. It is well known that the conserved disulfide bridge between Cys112 in the first and Cys192 in the second extracellular loop ensures correct folding of these loops and, as a consequence, the establishment of the ligand-binding domain. It is assumed that the introduction of additional cysteine residues as a result of mutations found in NDI (R181C, G185C, R202C, Y205C) might impair receptor function by altering disulfide-bonding of the conserved cysteine residues [39] or, alternatively, by introducing an additional disulfide bond [43] . Based on the finding of class IV mutations in transmembrane domains (I, II, VI), it can be concluded that several amino acids in these domains are involved in forming the conformation of the receptor for agonist binding.
Genotype-phenotype correlation in X-linked NDI?
Almost all mutations in the V 2 receptor gene result in a uniform clinical NDI phenotype with polyuric manifestations in the first weeks of life and poor growth. There are, however, a few exceptions to this rule. Three mutations (D85N, G201D, and P322S) are associated with a milder form of NDI, characterized by a later manifestation, around the age of 10 years, and without growth retardation. Functional studies of these mutations by in vitro expression systems have confirmed the partial phenotype of the NDI. P322S is the most remarkable of these three mutations, since another mutation substituting proline 322, namely P322H, is associated with a severe phenotype. By in vitro expression of both P322H and P322S in COS-7 cells, Ala et al. [39] have shown that the P322H mutant had totally lost the ability to stimulate the Gs/adenylate-cyclase system, whereas the P322S mutant was able to stimulate adenylate cyclase, albeit less than the wild-type receptor. Thus, the in vitro experiments closely correspond to the clinical phenotype. On the basis of three-dimensional modeling of the P322H and P322S mutant receptors, a plausible hypothesis to explain the molecular basis for the mild phenotype of the P322S has been proposed [39] . According to this model, Pro322 in the seventh transmembrane domain is spatially close to Asp85 located in the second transmembrane domain. In the vasopressin type 1 receptor, Asp85 is known to be important for the coupling properties of the receptor [44] . In the P322H mutant, modeling studies suggest the existence of a hydrogen bond between Asp85 and His322, which is possible in view of the close proximity of the histidine side chain to the carboxyl group of Asp85. This interaction could lead to a conformational constraint of the receptor, which prevents the coupling to the Gs/adenylate cyclase system. For the P322S mutant, such an interaction is not possible since the serine side chain is too far away to interact with Asp85, which allows partial activation of the receptor and of adenylate cyclase.
The autosomal recessive and dominant forms of NDI Both the autosomal recessive and the autosomal dominant types of NDI are caused by mutations in the aquaporin-2 water channel gene (Genbank accession number Z29491). The human AQP2 gene is a small gene consisting of four exons, comprising 5-kb genomic DNA. The 1.5-kb mRNA encodes a protein of 271 amino acids which has a predicted molecular weight of 29 kDa [45] . Like other aquaporins, AQP2 is assembled in the membrane as a homotetramer in which each 29-kDA monomer, consisting of six membrane spanning α-helical domains and intracellular N-and C-termini, is a functional water channel. The six transmembrane domains are connected by five loops (A through E). In the hourglass hypothesis, loops B and E are assumed to fold back into the membrane and to interact via their highly conserved motifs asparagine-prolinealanine (NPA boxes) to form the water pore [46] . Recent cryo-EM analysis of AQP1 crystals at atomic resolution revealed that this was indeed the case [47] .
To date 19 mutations in AQP2 have been identified in families with autosomal recessive NDI [review in 34].
These include 17 missense mutations, 1 nonsense mutation and a 1-bp deletion. All these mutations are found between the first and the last transmembrane domain. Upon expression in Xenopus leavis oocytes, all AQP2 missense mutants are impaired in their export from the endoplasmic reticulum (ER), presumably caused by misfolding of the mutants (class II) [48, 49] . An exception to the rule might be AQP2-T125M and AQP2-G175R, which have been reported to be non-functional water channels, unaffected in their routing to the plasma membrane [50] . At high expression levels in oocytes, however, four mutants (G64R, T126M, A147T, and L22V) appeared to confer water permeability [49, 51] . This finding indicates that at high expression levels a proportion of the AQP2 mutant proteins escapes from the ER and is routed to the plasma membrane [52] . Several families have been described with autosomal dominant NDI, based on the transmission of the disease from father to son. In one of these families, dominant NDI was caused by a mutation in one allele of the AQP2 gene of the affected patients [5, 53] . The identified point mutation (G866A) leads to the substitution of a lysine for a glutamic acid at position 258 (E258K) in the C-terminal tail of AQP2. By an elegant in vitro expression in oocytes cells using immunoblot and microscopic studies, this mutant was shown to be retarded in the Golgi region. Upon coexpression, it was shown that mutant heterotetramerizes with wild-type AQP2, consequently hindering further transport of the wild-type AQP2 to the plasma membrane [5] . The latter finding explains the dominant-negative effect of the E258K mutation.
Differential diagnosis between the X-linked and the autosomal forms of NDI
Patients with X-linked NDI can be discriminated from patients with autosomal NDI on the basis of their extrarenal reaction to administration of the synthetic V2-vasopressin analogue 1-desamino-8-D-arginine vasopressin (DDAVPP). Patients with autosomal NDI show normal increases in von Willebrand factor, factor VIII, and tissue-type plasminogen activator levels, whereas in patients with X-linked NDI these external responses are absent as a result of an extrarenal mutant V2R [54] .
Therapeutic potentials
Conventional therapy for NDI consists of adequate fluid supply and administration of the combination of two drugs: hydrochlorothiazide combined with either indomethacin or amiloride. Although indomethacin may have a positive influence on growth, the combination with amiloride is preferred, since on the long term it is associated with fewer side effects. For a long time the following mechanism for the paradoxical effect of thiazides in NDI has been proposed: thiazides reduce sodium reabsorption in the distal tubule by inhibition of the NaCl co-transporter (NCC). This subsequently results in increased sodium excretion, extracellular volume contraction, decreased glomerular filtration rate, and increased proximal sodium and water reabsorption. Consequently, less water and sodium reach the collecting tubules and less water is excreted. Recently, this long-standing hypothesis has been challenged by Magaldi, who reported new insights into the possible mechanism of action, based on microperfusion studies in rat inner medullary collecting duct (IMCD) [55, 56] . In these studies it was shown that in the absence of vasopressin, hydrochlorothiazide, when added to the luminal side, increased osmotic and diffusional water permeabilities. Increased permeability will facilitate water reabsorption in the collecting duct and thus decrease water excretion. When prostaglandins were added, the effect of thiazides decreased. This finding may offer one explanation why indomethacin potentiates the effect of thiazides in NDI. Altogether, the results of these microperfusion studies indicate that thiazides act in nephron segments beyond the distal tubule. Since the effect of thiazides was only seen when they were applied to the luminal side of the IMCD, it can be concluded that they do not interact with the basolaterally located V2R directly. In his paper, Magaldi proposed the possibility that these drugs act at some point in the vasopressin cascade inside the cell, based on the observation that an inhibitor of protein kinase-A blocked the effect of thiazide [56] .
Based on the fact that the majority of V2R mutations found in X-linked NDI and all AQP2 mutations found in autosomal recessive NDI are retained within the endoplasmic reticulum (class II), a treatment aimed at restoring the plasma membrane routing of ER-retained but otherwise functional V2R or AQP2 mutants, shows interesting potential. Indeed, Morello et al. have recently shown in vitro that selective, non-peptide cell-permeant V2R antagonists increased cell-surface expression and rescued the function of V2R mutants by promoting their maturation and targeting to the plasma membrane [57] . Thus, these V2R antagonists function as pharmacological chaperones, through stabilization of the protein conformation(s), which allows their export from the ER quality control apparatus. This in vitro observation may have important clinical implications since it offers a new therapeutic avenue for the treatment of NDI. The fact that eight distinct mutants could be functionally rescued by the same non-peptidic V2R antagonist is promising, in view of the enormous diversity of mutations identified in NDI. An additional interesting detail, in view of the potential clinical applicability of these V2R antagonists, was the observation that the functional rescue of cells expressing intracellularly retarded NDI mutants lasted for at least 24 h after removal of the antagonists. Similarly, it has been shown that treatment of cells, expressing ER-retarded AQP2 mutants with chemical chaperones, such as glycerol, facilitated the translocation of these mutants to the plasma membrane [58] . The feasibility of treatment with pharmacological and chemical chaperones of course needs to be tested in vivo. Although in vitro studies have suggested that in the future gene therapy for NDI may become technically feasible [59] , there are questions as to whether gene therapy would be the treatment of choice for this disorder and, even if so, it will certainly take a long time before the therapeutic potential of this form of therapy can be assessed. Therefore, developments of gene transfer vectors and gene delivery techniques and analysis of gene therapy safety need to be pursued and facilitated in order to determine the feasibility of gene therapy in renal diseases, such as NDI. In this respect, the recently developed transgenic mice carrying a functionally inactive V2R receptor protein [60] and the AQP2 knock-in mice [61] are of importance.
14. Chou C-L, Yip K-P, Michea L, Kador K, Ferraris JD, Wade Two observations suggest that nephritic factors (NFs) may be nephritogenic. First, glomerulonephritis is present in unusual frequency in three conditions in which the function of factor H is blocked, a dysfunction also produced by NFS: Second, in membranoproliferative glomerulonephritis (MPGN) type 2, subepithelial deposits on the paramesangial portion of the glomerular basement membrane are found only in renal biopsy specimens obtained during hypocomplementemia when NF is presumably present. In the present study, the composition of these deposits with respect to C3 derivatives was assessed by immunohistological evaluation using anti-C3c and anti-C3d. The assessment used routinely obtained photomicrographs, as well as immunohistologic examination of freshly cut tissue using the double-antibody method. Deposits in patients with typical hypocomplementemic MPGN type 2 reacted only with anti-C3c, whereas those in two patients with rapidly progressive MPGN type 2, six patients with poststreptococcal acute glomerulonephritis, and five patients with juvenile acute nonproliferative glomerulitis reacted with anti-C3d, as well as anti-C3c. Because all products derived from the breakdown of C3 except C3c react with anti-C3d, the deposits in typical MPGN type 2 must be composed only of C3c. With complete breakdown of bound C3b, C3c is released into the fluid phase. Therefore, the C3c in the deposits cannot be a product of a glomerular complement reaction, but instead must be formed in the circulation by the reaction of NF with native C3. Supporting C3c as the only constituent of these deposits is the observation that they are devoid of properdin and C5 is present in only small amounts.
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Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney Whether specific metabolic abnormalities are related to nephrolithiasis in patients with medullary sponge kidney (MSK) remains a debated issue. The purpose of this study is to determine metabolic disorders in patients with MSK and nephrolithiasis compared with idiopathic calcium-stone-forming patients. One hundred eighty-four patients with recurrent calcium-stone formations were investigated with regard to metabolic abnormalities. Of these, 22 patients (11.9%; 13 men, 9 women) showed MSK by radiological examination. MSK was defined as a kidney that presented at least three linear or round papillary opacities in the affected papilla on urography. Multiple stones (more than five) existed in both kidneys in all patients with MSK. The remaining 162 patients (109 men, 53 women) were idiopathic calcium-stone formers. Frequencies of low urine volume (urine < 1,500 mL/24 h) and hyperoxaluria (oxalate > 40 mg/24 h) were similar between the groups. Hypercalciuria (men, calcium > 300 mg/24 h; women, calcium of 250 mg/24 h) was found less frequently in the MSK group. The frequency of hypocitraturia (citrate < 300 mg/24 h) was significantly greater in the MSK group than the idiopathic group (77.3% versus 33.9%, respectively). Mean 24-hour urinary excretions of calcium, citrate, uric acid, and magnesium were significantly less in the MSK group. No differences were found in serum calcium, phosphate, and parathyroid hormone levels between the groups. Low urinary excretions of citrate and magnesium are the most typical metabolic disorders that distinguish MSK stone patients from idiopathic calcium-stone-forming patients. In addition to such anatomic abnormalities as ectatic collecting ducts, low levels of urinary inhibitors of stones seem to contribute to the pathogenesis of nephrolithiasis in patients with MSK.
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